Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 8/20 | 0.47 |
| ▸ | GAB1 | Q13480 | 2/20 | 0.45 |
| ▸ | IRS1 | P35568 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611585 | 0.91 | KMT2A (0.55) | HSD17B1HSD11B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3616155 | 0.88 | KMT2A (0.55) | HSD17B1HSD11B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3610724 | 0.87 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7093275 | 0.86 | KMT2A (0.56) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3621762 | 0.85 | ALDH1A1 (0.64) | HSD17B1HSD11B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5832128 | 0.83 | AKT1 (0.47) | HSD17B1HSD11B1HSD17B2ALDH1A1AKT1 | |
| SCHEMBL3611363 | 0.80 | HPGD (0.51) | HSD17B1HSD11B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5831475 | 0.80 | AKT1 (0.67) | ALDH1A1PKMAKT1GAB1IRS1 | |
| SCHEMBL3602414 | 0.79 | HSD11B1 (0.49) | HSD17B1HSD11B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3251192 | 0.79 | AKT1 (0.48) | ALDH1A1AKT1GAB1IRS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | claimed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | claimed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | HSD17B1 2/4885HSD11B1 1/4885HSD17B2 5/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD17B1 2/4885HSD11B1 1/4885HSD17B2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.